The prognostic value of UHRF-1 and p53 in gastric cancer

• Published in: Saudi journal of gastroenterology Vol. 22; no. 1; pp. 25 - 29
• Main Authors: Babacan, Nalan A, Egilmez, Hatice Reyhan, Yücel, Birsen, Ilknur, Parlak, Seker, Mehmet Metin, Kacan, Turgut, Bahceci, Aykut, Cihan, Sener, Akinci, Bülent, Eriten, Berna, Kilickap, Saadettin
• Format: Journal Article
• Language: English
• Published: India Medknow Publications and Media Pvt. Ltd 01-01-2016; Medknow Publications & Media Pvt. Ltd; Medknow Publications & Media Pvt Ltd; Wolters Kluwer Medknow Publications
• Subjects: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor - biosynthesis; CCAAT-Enhancer-Binding Proteins - biosynthesis; Development and progression; Diagnosis; Female; Gastric cancer; Gastritis - metabolism; Gastritis - pathology; Health aspects; Humans; Male; Middle Aged; Original; p53 genes; Prognosis; Stomach cancer; Stomach Neoplasms - diagnosis; Stomach Neoplasms - metabolism; Stomach Neoplasms - pathology; survival; Survival Analysis; Tumor proteins; Tumor Suppressor Protein p53 - biosynthesis; UHRF-1 protein; Young Adult; Zinc finger proteins; Saudi Arabia
• ISSN: 1319-3767; 1998-4049
• DOI: 10.4103/1319-3767.173755

This study aimed to examine whether UHRF-1 and p53 overexpression is a prognostic marker for gastric cancer.
Sixty-four patients with gastric cancer (study group) and 23 patients with gastritis (control group) were evaluated. Immunohistochemistry was used to examine expression of UHRF-1 and p53 in gastric cancers and a control group diagnosed with gastritis.
The median age was 63 years (18-83 years) in the study group. UHRF-1 was positive in 15 (23%) patients with gastric cancer and fi ve (21.7%) patients with gastritis (P = 0.559). UHRF1 expression level in gastric cancer is more powerful than in gastritis (P = 0.046). Thirty-seven (61%) patients with gastric cancer and only one patient with gastritis were p53 positive (P < 0.001). After a median follow-up of 12 months (1-110), the 2-year overall survival rates were 55% and 30% in negative and positive p53, respectively (P = 0.084). Also, the 2-year overall survival rates were 45% and 53% in negative and positive UHRF-1, respectively (P = 0.132).
According to this study, UHRF-1 and p53 were not prognostic factors for gastric cancer, whereas they may have a diagnostic value for differentiating between gastric cancer and gastritis.